US 11254725
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
granted A61KA61K38/00A61K38/47
Quick answer
US patent 11254725 (Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BIOMARIN PHARMACEUTICAL INC.
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K38/00, A61K38/47, A61P, A61P3/00